Cryptococcal Meningitis Clinical Trial
Official title:
A Multi-center, Prospective, Randomized Trial of Amphotericin B in the Initial Antifungal Therapy for Non-HIV Cryptococcal Meningitis Patients
Cryptococcus neoformans and C. gatti are important causes of central nervous system (CNS) infections with significant mortality, remaining a great public health challenge worldwide. Commonly seen as an opportunistic infection in adults with HIV/AIDS, cryptococcal meningitis (CM) accounts for 15% of HIV-related mortality globally [1]. In addition, a growing number of non-HIV CM patients have been observed in recent years with fatality approaching 30% in some areas [2,3]. It occurs in both those with natural or iatrogenic immunosuppression, as well as the apparently immunocompetent individuals. Approximately 65-70% of non-HIV CM patients were without any predisposing factors, particularly in the East Asia [4,5]. With the increasing number of hematopoietic stem cell transplantation, solid organ transplantation recipients and administration of immunosuppressive and corticosteroids agents, this illness will assume even greater public health significance. Current Infectious Disease Society of America (IDSA) guideline suggest the use of combination antifungal therapy: normal dose amphotericin (0.7-1mg/kg/day) combined with flucytosine for a minimum of 4 weeks, followed by fluconazole (600-800 mg/day) for a minimum of 10 weeks in total for HIV patients [6]. However, for non-HIV and immunocompetent patients, the treatment remains controversial. IDSA guideline recommended that the treatment of non-HIV patients could refer to the treatment of HIV patients. That is, amphotericin B combined with flucytosine is still administered in the induction period. However, as amphotericin B have nonspecific effect on ergosterol, it has strong side effects (hepatorenal toxicity, electrolyte disorder, anemia, ventricular fibrillation, etc.). Therefore, the dose of amphotericin B may not be appropriate for Asian patients due to the different drug metabolism and pharmacokinetic. In the prospective studies of Bennett[7] and Dismuke[8], low dose amphotericin B (0.3 mg/kg/d) combined with flucytosine achieved response rates of 66% and 85% at 6 weeks, respectively. A similar conclusion was also extracted from a large multicenter retrospective study that low dose amphotericin B (<0.7 mg/kg/d) combined with flucytosine for a minimum of 2 weeks, followed by fluconazole could achieve a response rate of 84%, indicating that the efficacy of low dose amphotericin B (< 0.7 mg/kg/d) may be equivalent with normal dose in non-HIV patients. Therefore, we plan to conduct a prospective, multicenter, open-label randomized controlled study to compare the efficacy and safety of normal dose amphotericin B (0.7 mg/kg/ d) and low dose amphotericin B (0.5 mg/kg/d) in the initial antifungal treatment for non-HIV cryptococcal meningitis patients.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01589289 -
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
|
Phase 3 | |
Completed |
NCT00976040 -
Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis
|
Phase 4 | |
Completed |
NCT04031833 -
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
|
Phase 1/Phase 2 | |
Completed |
NCT00830856 -
Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa
|
N/A | |
Completed |
NCT04532463 -
Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis
|
||
Completed |
NCT02098525 -
Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy
|
N/A | |
Completed |
NCT01075152 -
Cryptococcal Optimal ART Timing Trial
|
Phase 4 | |
Active, not recruiting |
NCT01715922 -
Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa
|
Phase 2/Phase 3 | |
Completed |
NCT00145249 -
Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
|
Phase 2 | |
Completed |
NCT01802385 -
Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis
|
Phase 3 | |
Terminated |
NCT00324025 -
Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS
|
Phase 2 | |
Completed |
NCT02955862 -
Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report
|
Phase 1 | |
Recruiting |
NCT03945448 -
Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02624453 -
Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS
|
N/A | |
Recruiting |
NCT00867269 -
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
|
||
Completed |
NCT01535469 -
Operational Research for Cryptococcal Antigen Screening
|
Phase 4 | |
Active, not recruiting |
NCT04072640 -
Three Induction Treatments on Cryptococcal Meningitis
|
Early Phase 1 | |
Not yet recruiting |
NCT05541107 -
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
|
Phase 3 | |
Not yet recruiting |
NCT02686853 -
Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis
|
Phase 4 | |
Not yet recruiting |
NCT04140461 -
AmB Dose for Cryptococcal Meningitis
|
Phase 3 |